CD274 and non-small cell lung carcinoma: Results from a real-world study in PD-L1-naïve patients with advanced non-small cell lung cancer (n = 640) treated with a PD-L1 blocker demonstrated that pre-treatment with prednisone (≥ 10 mg) was associated with decreased overall response rate, progression-free survival, and overall survival [55].